NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT04960709 2026-04-14
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT03682068 2026-02-03
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT03601455 2025-04-13
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05120622 2023-10-31
Rideau
University of British Columbia
Phase 1/2 Withdrawn
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03430895 2021-12-01
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT00880854 2019-11-15
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT03150836 2017-10-19
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn